Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 14/20 | 0.45 |
| ▸ | GUCY1A2 | P33402 | 14/20 | 0.45 |
| ▸ | GUCY1A1 | Q02108 | 14/20 | 0.45 |
| ▸ | GUCY1B1 | Q02153 | 14/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402956 | 0.90 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL16403518 | 0.86 | GUCY1B2 (0.43) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL18570193 | 0.85 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL19414210 | 0.85 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16402699 | 0.85 | GUCY1B2 (0.57) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL18570328 | 0.85 | CYP3A4 (0.52) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL16403535 | 0.83 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL20528787 | 0.83 | ATP4A (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL19492087 | 0.81 | GUCY1B2 (0.43) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP1A2 | |
| SCHEMBL19012013 | 0.81 | ATP4A (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| EP-3004094-B1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-3004094-B1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160122341-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122341-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122341-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| EP-3004094-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195333-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122341-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | PNPO, PAH, TNNI3 | GUCY1B2 1428/4885GUCY1A2 716/4885GUCY1A1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.